|Articles|February 1, 2020
- BioPharm International-02-01-2020
- Volume 33
- Issue 2
BioPharm International, February 2020 Issue (PDF)
Click the title above to open the BioPharm International February 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
Managing Risk for Cell and Gene Therapy Logisticsalmost 6 years ago
The Call for a Rapid Responsealmost 6 years ago
Data Management Practicesalmost 6 years ago
Biopharma Analysis Benefits from New Technology and Methodsalmost 6 years ago
Cell Therapies: The Living End of Growth Opportunitiesalmost 6 years ago
Fresh Thinking in Biologic Drug Formulationalmost 6 years ago
The Need for Advanced Process Modeling for New Therapeutic Biologicsalmost 6 years ago
Cell Culture Variables for Gene Therapy Vectorsalmost 6 years ago
Challenges in Vector Purification for Gene TherapyNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
2
Implementing Automation and Flexible Design for Allogeneic Manufacturing
3
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
4
Rentschler–Coriolis Partnership Reflects Demand for Connected Biopharma Workflows
5
